ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK) rearrangements lead to an in-frame fusion protein with oncogenic activity and are detected in approximately 5% of non-small cell lung cancer (NSCLC) cases [2, 3].